IRIS
ANGARANO, Gioacchino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.129
AS - Asia 7.891
EU - Europa 6.004
SA - Sud America 2.283
AF - Africa 285
Continente sconosciuto - Info sul continente non disponibili 14
OC - Oceania 9
AN - Antartide 2
Totale 38.617
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.949
SG - Singapore 3.404
BR - Brasile 1.972
CN - Cina 1.927
HK - Hong Kong 1.461
DE - Germania 1.430
SE - Svezia 870
UA - Ucraina 824
RU - Federazione Russa 729
IT - Italia 685
FI - Finlandia 525
GB - Regno Unito 438
VN - Vietnam 438
IN - India 152
AR - Argentina 126
CI - Costa d'Avorio 120
FR - Francia 108
CA - Canada 79
BD - Bangladesh 78
ID - Indonesia 73
BE - Belgio 66
MX - Messico 59
ZA - Sudafrica 57
EC - Ecuador 56
IE - Irlanda 54
TR - Turchia 51
PL - Polonia 49
IQ - Iraq 40
CO - Colombia 35
ES - Italia 35
JP - Giappone 35
AT - Austria 31
NL - Olanda 30
PY - Paraguay 29
MK - Macedonia 27
PK - Pakistan 27
SA - Arabia Saudita 27
IR - Iran 26
UZ - Uzbekistan 22
KE - Kenya 21
VE - Venezuela 21
MA - Marocco 20
TN - Tunisia 17
CL - Cile 15
IL - Israele 15
JO - Giordania 15
EG - Egitto 14
LT - Lituania 13
PE - Perù 13
AE - Emirati Arabi Uniti 12
NP - Nepal 12
RO - Romania 11
UY - Uruguay 11
CZ - Repubblica Ceca 10
EU - Europa 10
GR - Grecia 10
HR - Croazia 10
AZ - Azerbaigian 9
GE - Georgia 9
KZ - Kazakistan 9
RS - Serbia 9
BG - Bulgaria 8
DZ - Algeria 8
HN - Honduras 8
AU - Australia 7
ET - Etiopia 7
LB - Libano 7
OM - Oman 7
BY - Bielorussia 6
CR - Costa Rica 6
JM - Giamaica 6
MY - Malesia 6
CH - Svizzera 5
PS - Palestinian Territory 5
AL - Albania 4
BH - Bahrain 4
HU - Ungheria 4
NG - Nigeria 4
SN - Senegal 4
TT - Trinidad e Tobago 4
BB - Barbados 3
BO - Bolivia 3
BW - Botswana 3
DO - Repubblica Dominicana 3
LV - Lettonia 3
NI - Nicaragua 3
PA - Panama 3
PH - Filippine 3
PT - Portogallo 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AQ - Antartide 2
CG - Congo 2
GH - Ghana 2
KH - Cambogia 2
KR - Corea 2
KW - Kuwait 2
LU - Lussemburgo 2
LY - Libia 2
SV - El Salvador 2
Totale 38.591
Salva come PNG Salva come JPEG
Città #
Fairfield 2.714
Woodbridge 1.990
Jacksonville 1.861
Ashburn 1.756
Chandler 1.710
Singapore 1.652
Houston 1.495
Hong Kong 1.444
Seattle 1.118
Wilmington 1.004
Cambridge 909
Ann Arbor 840
Nyköping 580
Beijing 474
Lawrence 466
Roxbury 464
Dallas 459
Nanjing 447
New York 316
Des Moines 288
Boardman 279
Los Angeles 244
Princeton 232
São Paulo 162
Ho Chi Minh City 136
Shenyang 126
Bari 123
Abidjan 120
Hebei 120
Inglewood 119
Buffalo 118
Santa Clara 115
San Diego 113
Munich 112
Dearborn 111
Nanchang 110
Brooklyn 94
Hanoi 84
Helsinki 73
Jiaxing 73
Tianjin 69
London 67
Rio de Janeiro 61
Dublin 53
Brussels 51
Rome 47
Dong Ket 46
Moscow 44
Belo Horizonte 43
Guangzhou 43
Jakarta 41
Milan 41
Pune 40
Warsaw 40
Brasília 39
Changsha 38
Curitiba 37
Chicago 36
Tokyo 33
Paris 31
Hefei 29
Atlanta 27
Johannesburg 27
Porto Alegre 27
Taranto 27
Denver 26
Salvador 25
Campinas 24
Montreal 24
San Francisco 24
Stockholm 24
Mexico City 23
The Dalles 23
Turku 23
Auburn Hills 22
Jinan 22
Washington 22
Zhengzhou 22
Boston 21
Columbus 21
Falls Church 21
Kunming 21
Norwalk 21
Nuremberg 21
Council Bluffs 20
Guayaquil 20
Nairobi 19
Redwood City 19
Toronto 19
Chennai 18
Da Nang 18
Tashkent 18
Dhaka 17
Goiânia 17
Asunción 15
Fortaleza 15
Haiphong 15
Mumbai 15
Ningbo 15
San Mateo 15
Totale 26.393
Salva come PNG Salva come JPEG
Nome #
Anemia as a risk factor for disease progression in patients admitted for COVID-19: data from a large, multicenter cohort study 362
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 354
Influence of HLA-B18 on liver fibrosis progression in a cohort of HIV/HCV coinfected individuals 341
Economic evaluation of HIV treatments: The I.CO.N.A. cohort study 220
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 200
Access to health services for undocumented immigrants in Apulia. 184
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 184
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART 170
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? 167
Variability OF HIV-1 V2 env domain for integrin binding: Clinical correlates 165
HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen 162
An outbreak of HIV-1 BC recombinants in Southern Italy 159
Access to HAART in HIV-Infected Immigrants: A Retrospective Multicenter Italian Study 159
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 153
Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood–brain barrier damage 153
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. 151
Cryptosporidiosis in the acquired immunodeficiency syndrome: a case report 149
An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia 148
Sphingomonas paucimobilis outbreak in a dialysis room: Case report and literature review of an emerging healthcare associated infection 144
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 142
Comment on: Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection 142
A cyanobacterium-like body found in the stools of an HIV+ patient with diarrhoea 141
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 141
Chronic Inflammation in a Long-Term Cohort of HIV-Infected Patients According to the Normalization of the CD4:CD8 Ratio 139
The elderly and direct antiviral agents: Constraint or challenge? 139
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. 138
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 138
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 138
Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study. 137
Co-receptor switch during HAART is independent of virological success 136
Prevalence of urinary schistosomiasis in migrants in Apulia, a region of southern Italy, in the years 2006-2016 136
Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy 136
Local epidemics gone viral: Evolution and diffusion of the Italian HIV-1 recombinant form CRF60_BC 135
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 135
Improved virological outcome in non-B patients: a possible role for baseline coreceptor tropism 134
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients 134
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 133
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 133
Access to Health Services for Undocumented Immigrants in Apulia 132
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort. 132
Cryoglobulinemia in subjects with HCV infection alone, HIV infection and HCV/HIV coinfection 131
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study 131
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 129
" INFEZIONI DA CLAMYDIA PNEUMONIAE IN PAZIENTI CON A.I.D.S. " 128
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies 126
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA <50 cp/mL 126
Alterazioni oftalmoscopiche e fluorangiografiche in pazienti affetti da AIDS 125
Persistence of e antigen as prognostic marker in acute hepatitis B 125
HIV-1 coreceptor tropism: A syllogistic connection with the veterans aging cohort study index and the CD4/CD8 ratio 125
Limiting severe outcomes and impact on intensive care units of moderate-intermediate 2009 pandemic influenza: role of infectious diseases units. 124
Renal function changes in HCV-infected patients with chronic kidney disease during and after treatment with direct antiviral agents 124
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). 123
Intrathecal immune response in human immunodeficiency virus infection 122
Hepatic encephalopathy in the course of anti-HCV therapy with paritaprevir/ritonavir, ombitasvir, dasabuvir and ribavirin 121
Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients 120
Long-term efficacy and safety of switching from lamivudine + adefovir to tenofovir disoproxil fumarate in virologically suppressed patients 119
HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples 118
A multidrug-resistant (MDR) HIV type 1 infection in a homosexual man and identified source patient 118
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 118
Incidence of tuberculosis among HIV-Infected patients receiving highly active antiretroviral therapy in Europe and North America 118
HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic 116
CD4 and CD4/CD8 ratio progression in HIV-HCV infected patients after achievement of SVR 116
Evolution of antiretroviral prescription and response over a period of 8 years: An Italian multicentre observational prospective cohort study 116
Are the proposed env mutations actually associated with resistance to maraviroc? 116
Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study 115
Premature lesions of the carotid vessels in HIV-1 infected patients treated with protease inhibitors 115
Adherence of hiv patients switching to emtricitabina+tenofovir disoproxil+rilpivirin. Real world evidence from italian administrative databases 115
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 115
Splenic abscesses as a first manifestation of Crohn's disease: A case report 115
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 114
Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection 113
HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years 112
Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens 112
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 112
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 112
Hepatitis B virus markers, alpha-fetoprotein and survival in fulminant viral hepatitis 111
Reduced concentrations of HIV-RNA and TNF-alpha coexist in CSF of AIDS patients with progressive multifocal leukoencephalopathy 111
Epidemiological multicentric Italian society of infectious and tropical diseases study on prevalence of tropical diseases in hospitalized immigrants in Italy during 2002 111
Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study 111
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 111
Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART 111
Parkinsonism in a patient with AIDS and cerebral opportunistic granulomatous lesions 110
Difficulties in classifying a/g recombinants: methodological problems or genetic variability? 110
V3 sequences and paired HIV isolates from 52 non-subtype B HIV type 1-infected patients 110
HIV-1 variability and progression to AIDS: a longitudinal study 110
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 110
Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects 109
Risk of AIDS in HIV seroconverters: a comparison between intravenous drug users and homosexual males 108
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 108
Frequent cervicovaginal shedding of HIV-1 in asymptomatic, non-severely immunodeficient women 107
Reproductive choice in individuals HIV-1 infected in South Eastern Italy 107
Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir 107
Radioimmunoassay diagnosis of hepatitis type A 106
An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy 106
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 106
Immunological markers in HIV-infected pregnant and non-pregnant women 106
Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort 106
Cryptococcal Meningitis 105
Effects of HIV superinfection on HBV replication in a chronic HbsAg carrier with liver disease 105
Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study 105
Totale 13.488
Salva come PNG Salva come JPEG
Categoria #
all - tutte 166.103
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 166.103
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.296 0 0 0 0 0 211 469 203 445 536 249 183
2021/20222.793 111 370 36 232 137 183 103 196 183 170 452 620
2022/20234.454 799 318 186 449 634 519 40 505 776 34 102 92
2023/20241.506 144 345 83 75 96 394 39 39 28 41 30 192
2024/20256.295 90 118 690 215 110 546 337 560 279 324 940 2.086
2025/20266.800 1.862 727 1.105 1.555 1.321 230 0 0 0 0 0 0
Totale 39.280